Measure biomarkers at lower levels than ever before.
Digital health solution, Simoa, is changing the way in which the biology of health and disease is studied by giving researchers the ability to closely examine critical biomarkers. In doing so, Quanterix enables development of methods providing much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.
The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation, and infectious disease.
Simoa® Bead Technology
Quanterix’ digital biomarker detection technology, Simoa®, is changing the way in which the biology of health and disease is studied by giving researchers the ability to examine critical proteins and nucleic acids, at ultra low – even baseline – levels, in most common sample types.
- First of its kind detection capabilities
- Detect biomarkers at femtogram levels
- See results in record time
How it works
A high-level look at a Simoa Bead-based assay, from development to data analysis.
Paramagnetic particles coupled with antibodies designed to bind to specific targets are added to the sample.
Detection antibodies – capable of generating fluorescent product – are added.
The objective is to form an immunocomplex consisting of the bead, bound protein, and detection antibody.
At low concentrations, each bead will contain one bound protein, or none.
The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead.
Enzymatic signal amplification with fluorescent substrate, fluorescence imaging and data reduction.
Data analysis – results can be viewed and analyzed on the board or exported to commonly used software packages or LIMS systems.
Simoa® Planar Array Technology
An incredibly simple, flexible, robust, and ultra-sensitive immunoassay platform for measuring up to 10-plex biomarkers. Its unique capabilities are designed specifically to address many of today’s unmet needs in immuno-oncology and other research areas.
- Proprietary, high-precision, digital nanofluidic antibody deposition
- Reaction kinetics optimized by fluid dynamics
- Optimized image quality and dynamic range
How it works
A high level look at a Simoa Planar Array assay, from initiation to imaging.
96-well plates are spotted at the factory with the target analyte(s) of interest
Diluted samples and standards added to each well and the plates are to create a unique surface chemistry and “vortex” effect
Biotinylated detection antibodies are added to form the other half of the immunocomplex “sandwich”
High sensitivity HRP enzyme-conjugated streptavidin is added in between additional shake cycles.
Finally, a chemiluminescent substrate is added just prior to ultra-sensitive CCD camera imaging, in order to measure the signal intensity produced by each spot.
Reverse Phase Protein Array
Our unique soft-touch deposition technology enables printing of even complex biological samples onto a broad range of substrates such as slides, membranes, microtiter plate wells, disks, wafers, and chips
- Unmatched sample flexibilty
- Capable of printing on glass, plastic, nitrocellulose and many other surfaces
- High density printing with unequaled accuracy
- User-friendly software interface
SP-X Imaging and Analysis System™
Unleashing the power of next-generation Simoa® Planar Array technology for robust multiplex biomarker detection – even at healthy baseline levels.
Up to 1000x greater sensitivity
10 in 1
Up to 10 biomarkers in a single assay
Compatible with 100+ assays
Produces high quality microarrays of DNA, proteins, cell lysates and a variety of other samples using its proprietary soft touch deposition technology.
Unmatched sample flexibility
Prints on a variety of surfaces
High density printing for accuracy
Ready to take your biomarker research to the next level?request a quote
Simoa® Accelerator Laboratory
With the Simoa® Accelerator Laboratory as your pharma service technology solution of choice, you can expand the limits of biomarker exploration and dramatically accelerate the timeline to drug approvals.request more info